Pre-existing heart failure subtype and in-hospital mortality in liver transplantation: a nationwide analysis

Nithila Sivakumar; Chanokporn Puchongmart; Camila Padovese; Mohammed Abujulaydah; Ben Thiravetyan; Valmiki Maharaj

doi:10.18203/2320-6012.ijrms20264161

Authors

Nithila Sivakumar Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Chanokporn Puchongmart Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Camila Padovese Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Mohammed Abujulaydah Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Ben Thiravetyan Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Valmiki Maharaj Division of Cardiology, University of Minnesota, Minneapolis, minnesota, USA

DOI:

https://doi.org/10.18203/2320-6012.ijrms20264161

Keywords:

Heart failure, HFpEF, Liver transplantation, Mortality

Abstract

Background: Heart failure (HF) is increasingly encountered in liver transplant candidates, yet the influence of HF phenotype on perioperative outcomes remains unclear. We evaluated the association between pre-existing HF subtype and in-hospital mortality among liver transplant hospitalizations.

Methods: We conducted a retrospective cohort study of the National Inpatient Sample, 2016-2022. Adult liver transplant hospitalizations were stratified into no HF, chronic diastolic HF, and chronic systolic HF (surrogates for HF with preserved and reduced ejection fraction, respectively). The primary outcome was in-hospital mortality; secondary outcomes included acute kidney injury, acute HF, cardiogenic shock, cardiac arrest, discharge disposition, length of stay, and hospital charges. Survey-weighted multivariable logistic regression was adjusted for demographics, comorbidities, and hospital characteristics.

Results: Among 53,910 weighted hospitalizations, 98.1% had no HF, 1.5% had chronic diastolic HF, and 0.4% had chronic systolic HF. Patients with chronic diastolic HF were older with a greater comorbidity burden, including hypertension, diabetes, arrhythmias, and renal failure (all p<0.01). Unadjusted in-hospital mortality was higher in chronic diastolic HF (5.7%) and chronic systolic HF (7.0%) than in no HF (2.9%; p=0.03), as were acute kidney injury, cardiac arrest, length of stay, and charges. After adjustment, neither chronic diastolic HF (adjusted odds ratio 1.6, 95% confidence interval 0.7-3.4) nor chronic systolic HF (2.1, 0.7-6.7) was independently associated with mortality.

Conclusions: Pre-existing HF is associated with worse unadjusted outcomes in liver transplant hospitalizations, but HF subtype is not independently associated with in-hospital mortality after adjustment. Comorbidity burden, rather than HF phenotype, appears to drive mortality risk in this highly selected population.

References

Smilowitz NR, Banco D, Katz SD, Beckman JA, Berger JS. Association between heart failure and perioperative outcomes in patients undergoing non-cardiac surgery. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):68-75.

Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;150(19):e351-e442.

Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804-11.

Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology 2020;71(1):334-45.

Ying X, Oje AO, De Witte AJ, Slaughter JC, Spann AL, Jesudian AB, et al. Severity of liver disease is associated with cirrhotic cardiomyopathy: a multicenter study. Liver Transpl 2026;32(4):539-48.

VanWagner LB, Lapin B, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, et al. High early cardiovascular mortality after liver transplantation. Liver Transpl 2014;20(11):1306-16.

VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. Am J Transplant 2018;18(1):30-42.

Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun 2023;8(1):e0352.

Harinstein ME, Gandolfo C, Gruttadauria S, Accardo C, Crespo G, VanWagner LB, et al. Cardiovascular disease assessment and management in liver transplantation. Eur Heart J 2024;45(41):4399-413.

Cheng XS, VanWagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP, et al. Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association. Circulation 2022;146(21):e299-e324.

Levy PE, Khan SS, VanWagner LB. Cardiac evaluation of the kidney or liver transplant candidate. Curr Opin Organ Transplant 2021;26(1):77-84.

Shin WJ, Kwon HM, Kim SH, Jang HY, Kim JY, Kim JH, et al. Characterizing heart failure with preserved ejection fraction in end-stage liver disease and liver transplant outcomes. JACC Asia 2023;3(Part 3):506-17.

Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates. Circulation 2012;126(5):617-63.

Lentine KL, Xiao H, Brennan DC, Schnitzler MA, Villines TC, Abbott KC, et al. The impact of kidney transplantation on heart failure risk varies with candidate body mass index. Am Heart J 2009;158(6):972-82.

Furey G, Moros D, Tong MZY. Mitigation of cardiac disease during liver transplantation through concomitant cardiac surgery and liver transplant: pushing the boundaries of acceptable surgical candidacy. J Liver Transplant 2024;15:100229.

Rangaswami J, Bangalore S, Kaplan B, Birdwell KA, Wiseman AC, McCullough PA, et al. Cardiovascular disease care fragmentation in kidney transplantation: a call for action. Kidney Int 2019;96(3):568-71.

Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, et al. Sex differences in heart failure with preserved ejection fraction pathophysiology. JACC Heart Fail 2019;7(3):239-49.

Shah SJ, Kitzman DW, Borlaug BA, Van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation 2016;134(1):73-90.

Ghimire A, Al-Zaneen G, Michaud JB, Worthen G, Rampersad C, Singh SK, et al. Heart failure in kidney transplant recipients: narrative review of risk factors, therapy, and current gaps in management. Cardiol Ther 2026;15(1):1-23.

Kwon HM, Moon YJ, Jung KW, Park YS, Kim KS, Jun IG, et al. Appraisal of cardiac ejection fraction with liver disease severity: implication in post-liver transplantation mortality. Hepatol. 2020;71(4):1364-80.

Sharma V, Kleb C, Sheth C, Verma BR, Jain V, Sharma R, et al. Cardiac considerations in liver transplantation. Cleve Clin J Med 2022;89(1):46-55.

Khurmi NS, Chang YH, Eric Steidley D, Singer AL, Hewitt WR, Reddy KS, et al. Hospitalizations for cardiovascular disease after liver transplantation in the United States. Liver Transpl 2018;24(10):1398-410.

Izzy M, Fortune BE, Serper M, Bhave N, DeLemos A, Gallegos‐Orozco JF, et al. Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations. Am J Transplant 2022;22(12):2740-58.

Ross‐Driscoll K, Kramer M, Lynch R, Plantinga L, Wedd J, Patzer R. Variation in racial disparities in liver transplant outcomes across transplant centers in the United States. Liver Transpl 2021;27(4):558-67.

Mechelinck M, Hartmann B, Hamada S, Becker M, Andert A, Ulmer TF, et al. Global longitudinal strain at rest as an independent predictor of mortality in liver transplant candidates: a retrospective clinical study. J Clin Med 2020;9(8):2616.

Cailes B, Huber EL, Brick C, Farouque O, Majumdar A, Al-Fiadh A, Theuerle J, et al. Blunted cardiac reserve as a marker of cirrhotic cardiomyopathy: cardiac outcomes following liver transplantation and comparison to the existing guidelines. Am J Transplant 2025;25:1976-86.

Rachwan RJ, Kutkut I, Timsina LR, Chaaya RG, El-Am EA, Sabra M, et al. CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates. J Hepatol 2021;75(1):142-9.

Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011;58(3):223-31.

VanWagner LB, Ning H, Whitsett M, Levitsky J, Uttal S, Wilkins JT, et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score. Hepatology 2017;66(6):1968-79.